Showing results (1-10 of 46) with videos related to
Sort By:
Pageof 5
BMC Musculoskeletal Disorders|September 21, 2011
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort studySarika Ogale, Elena Hitraya, Henry J HenkCancer Treatment and Research Communications|February 21, 2022
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology networkEric Nadler, Anupama Vasudevan, Yunfei Wang, et al.Rheumatology and Therapy|October 18, 2016
Use of Anti-Tumor Necrosis Factor Therapy: A Retrospective Study of Monotherapy and Adherence to Combination Therapy with Non-Biologic Disease-Modifying Anti-Rheumatic DrugsNicole M Engel-Nitz, Sarika Ogale, Mahesh KulakodluHealth and Quality of Life Outcomes|July 4, 2014
Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysisJeroen P Jansen, Felicity Buckley, Fred Dejonckheere, et al.Journal of Managed Care & Specialty Pharmacy|November 30, 2020
A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER"Sarika Ogale, Clarissa Emy Higuchi Zerbini, Miranta Antoniou, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritisJosh J Carlson, Sarika Ogale, Fred Dejonckheere, et al.Cancer Medicine|November 24, 2022
Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United StatesRishika Sharma, Sarika Ogale, Nathaniel J Smith, et al.Clinical Therapeutics|January 30, 2010
Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims databaseElise M Pelletier, Sarika Ogale, Elaine Yu, et al.The Journal of Rheumatology|January 18, 2011
Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trialJin-Shei Lai, Jennifer L Beaumont, Sarika Ogale, et al.Drugs - Real World Outcomes|October 18, 2016
Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another BiologicStephen S Johnston, Donna McMorrow, Amanda M Farr, et al.Pageof 5